Observational studyRespiratory research2026
Real-world persistence with antifibrotic treatments: a nationwide study on claims data in France (The REPEAT study).
Observational study in Respiratory research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundLong-term persistence with antifibrotic drugs is crucial to slow disease progression in fibrosing ILDs but is challenging due to adverse events. Large-scale, real-world studies investigating modifiable healthcare system factors associated with persistence are lacking.
objectivesThe main objectives of this study were to assess the real-life persistence with antifibrotic treatments in the overall French population and to explore factors associated with patients' persistence with antifibrotic therapy.
methodsIn this retrospective observational study conducted using the French National Health Database System, all adults initiating nintedanib or pirfenidone between January 2019 and December 2021 were included. They were categorized by diagnosis (idiopathic pulmonary fibrosis, interstitial lung disease associated with systemic sclerosis, and progressive pulmonary fibrosis) using International Classification of Diseases 10th Revision codes. Persistence with antifibrotic therapy (defined as no treatment gap longer than 60 days), adherence to antifibrotic treatments, overall survival (OS), and event-free survival (EFS) were assessed. A multivariable Fine-Gray model identified factors associated with non-persistence.
resultsAmong 4,935 incident patients, the 12-month persistence rate with antifibrotic therapy was 70.8%. The median time of follow-up for incident patients was 27 months. The median time on antifibrotic therapy was 14.1 months. Switching between antifibrotics occurred in 16.6% of patients, mainly during the first year. At 12 months, OS and EFS were 85.8% and 57.4%, respectively, with lower rates observed among patients with IPF. Regular outpatient visits, follow-up in expert centers, and early supportive interventions (day-hospitalization, temporary treatment interruptions) were associated with increased persistence whereas suboptimal follow-up (< 2 pulmonary function tests during the follow-up period) was strongly associated with non-persistence (sHR = 3.1).
conclusionStructured patient follow-up and proactive management of adverse events, including treatment interruption, could be key to optimizing long-term persistence with antifibrotic therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.